Introduction
============

Neuroblastoma is a childhood tumor that mainly derives from neural crest progenitor cells [@B1], [@B2]. Despite its occupation rate of 8-10% of all pediatric cancer diagnoses, neuroblastoma disproportionately results in 12-15% of all childhood cancer related mortality [@B3]-[@B5]. It is characterized by widely clinical heterogeneity, spanning from spontaneous regression to therapy-refractory progression [@B6], [@B7]. Another reflection of such heterogeneity was the contrasting survival rate of different subgroup patients [@B8]. In patients with the low- and intermediate-risk neuroblastoma, the long-term survival rate is greater than 90%. However, in patients with the high-risk neuroblastoma, less than 40% could finally survived [@B9]-[@B12].

In the past decades, considerable progress has been made in understanding the genetic underpinnings of neuroblastoma. Exposed environmental factors of children and pregnant women were reported to predispose to neuroblastoma, but not finally defined [@B13], [@B14]. Mutations in *ALK* and *PHOX2B* were considered as two major causes of familial neuroblastoma. Other genetic variants in genes including*LMO1* [@B15],*BARD1* [@B16],*TP53* [@B17], *DUSP12* [@B18], *LIN28B* [@B19], *HACE1* [@B19], *NEFL* [@B20] and *CDKN1B* [@B21] have more recently been associated with neuroblastoma predisposition. Moreover, fine mapping study also identified neuroblastoma-associated functional risk SNPs in *BARD1* [@B22]. Taken together, however, all the current identified variants still could not fully elucidate the etiology of neuroblastoma. We still have a long way to fully reveal the genetic landscape of neuroblastoma. Identification of other somatic mutations and polymorphisms will further clarify the mechanisms of neuroblastoma.

Long non-coding RNAs (lncRNAs), longer than 200 nucleotides, are a class of non-protein-coding transcripts. LncRNAs regulate multiple physiological and pathological processes by different mechanisms, including transcriptional regulation, genome rearrangement, imprinting, epigenetic regulation, and chromatin modification. Accumulating evidence point to the critical role of lncRNAs in human disorders especially in cancers. *H19* gene was the first lncRNA discovered in the human genome [@B23], [@B24]. *H19* gene is exclusively expressed from maternal chromosome, treated as a paternally imprinted oncofetal gene [@B25]. *H19* gene is incompetent to encode for a protein, but instead encodes for a polyadenylated, spliced, and capped ncRNA spans 2.7kb long [@B23]. *H19* gene has been reported as a cancer-associated lncRNA that functions as both oncogene and suppressor gene. Mounting proof have been achieved in the modulation ability of single nucleotide polymorphisms (SNPs) within lncRNAs in causing tumor susceptibility. Thus far, most studies have addressed the identification of *H19* gene SNPs in bladder cancer [@B26], hepatocellular cancer [@B27], and lung cancer [@B28], whereas few studies focused on the role of *H19* gene SNPs in neuroblastoma risk. Here we conducted a six-center hospital-based case-control study aiming to investigate the association between SNPs within the *H19* gene and neuroblastoma risk.

Materials and Methods
=====================

Study subjects
--------------

The enrollment criteria of subjects were described in previous studies [@B29]-[@B32]. Prior to analysis, the study protocols were approved by the Institutional Review Board of each hospital. The current case-control study was carried out in 6 hospitals in 6 provinces of China. A total of 700 cases were pathology-confirmed with neuroblastoma, and classified clinical stages according to the INSS [@B33], and 1516 controls with no prior history of neuroblastoma were randomly enrolled in the same area as cases. To be specific, 275 cases and 531 controls were from Guangzhou Women and Children\'s Medical Center [@B34], 162 cases and 270 controls were from Hunan Children\'s Hospital [@B35], 118 cases and 281 controls were from The First Affiliated Hospital of Zhengzhou University [@B36], [@B37], 76 cases and 186 controls were from The Second Affiliated Hospital of Xi\'an Jiaotong University [@B38], 36 cases and 72 controls were from The Second Affiliated Hospital and Yuying Children\'s Hospital of Wenzhou Medical University [@B39], [@B40], and 33 cases and 176 controls were from Children\'s Hospital of Shanxi. All guardians of participants provided written informed consent.

Polymorphism selection and genotyping
-------------------------------------

We screened NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and SNPinfo (<http://snpinfo.niehs.nih.gov/snpfunc.htm>) to select potential functional neuroblastoma-risk SNPs. Three SNPs (rs2839698 G\>A, rs3024270 C\>G, rs217727 G\>A) in *H19* gene that met the previously described criteria were selected for inclusion [@B41]. The rs2839698 G\>A and rs3024270 C\>G are located in the transcription factor binding sites. As shown in Supplemental [Figure s1](#SM0){ref-type="supplementary-material"}, there was no significant linkage disequilibrium (R^2^\<0.8) among these three SNPs (R^2^=0.408 between rs217727 and rs3024270; R^2^=0.213 between rs217727 and rs2839698; R^2^=0.508 between rs3024270 and rs2839698). Genomic DNA was isolated from venous blood using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China). Genotype analysis of all three *H19* gene SNPs was undertaken using TaqMan SNP Genotyping Assay from Applied Biosystem using 7900 Real-Time PCR system [@B42]-[@B45]. Negative controls (with water) and duplicate test samples (10% of all the samples) were included in each 384-well plate. 100% concordant of genotypes in replicates were achieved.

Statistical analysis
--------------------

Tests for Hardy-Weinberg equilibrium (HWE) were conducted for each SNP separately among control subjects with the use of χ^2^ test. Differences in demographic variables between case subjects and control subjects were analyzed using the two-sided χ^2^ test. Neuroblastoma risk was determined as odds ratios (ORs) and 95% confidence intervals (CIs), based on unconditional logistic regression adjusted for age and gender. A *P*-value of \< 0.05 was used for statistical significance. The SAS release 9.1 (SAS Institute, Cary, NC) was used for statistical analyses.

Results
=======

Association between *H19* polymorphisms and neuroblastoma susceptibility
------------------------------------------------------------------------

We enrolled 700 cases with neuroblastoma and 1516 controls without neuroblastoma from 6 hospitals in 6 provinces of China ([Supplemental Table 1](#SM0){ref-type="supplementary-material"}), and no significant differences were observed between cases and controls for age (*P*=0.525) and gender (*P*=0.796). We successfully genotyped 700 controls and 1514 cases. The genotype distributions of *H19* gene polymorphisms (rs2839698 G\>A, rs3024270 C\>G, rs217727 G\>A) and their associations with neuroblastoma susceptibility were summarized in Table [1](#T1){ref-type="table"}. In the controls, the genotype frequencies of all the three SNPs conformed to Hardy-Weinberg equilibrium (HWE=0.406 for rs2839698 G\>A, HWE=0.162 for rs3024270 C\>G, HWE=0.744 for rs217727 G\>A). Our results indicated that none of the SNPs included were significantly associated with neuroblastoma susceptibility. We also failed to find significantly statistical correlation between the combined effect of risk genotypes and the susceptibility of neuroblastoma.

Stratification analysis
-----------------------

We further carried out stratified analysis to analyze the association between*H19* gene polymorphisms and neuroblastoma susceptibility under different subtypes including age, gender, tumor sites, and INSS stages (Table [2](#T2){ref-type="table"}). However, we still could not obtain significant association between all the three polymorphisms, neither in single nor combined analysis, and neuroblastoma susceptibility under all the strata.

Haplotype analysis
------------------

As shown in Table [3](#T3){ref-type="table"}, we failed to find any haplotype that was significantly associated with neuroblastoma risk.

Discussion
==========

In this study, we investigated whether lncRNA *H19* gene polymorphisms were involved in the risk of neuroblastoma in Chinese population using individuals from six centers. Our results showed that none of the *H19* gene polymorphisms contributed to the risk of neuroblastoma. Conclusions obtained here represent an important extension of our understanding of how *H19* gene polymorphism is not relevant to neuroblastoma risk.

The*H19* gene is located in human chromosome 11p15.5 locus. The expression level of *H19* gene peaks at the early stages of embryogenesis, then falls postnatally [@B46], [@B47], and is reactivated during tumorigenesis in some cancer types [@B48], [@B49]. The critical role of *H19* gene in carcinogenesis was intensively reported. Wada et al. [@B50] detected a maintenance of normal imprinting of the *H19* gene in neuroblastoma. Liang et al. [@B51] found that the lncRNA *H19* gene promotes epithelial to mesenchymal transition of colorectal cancer by functioning as part of miRNA sponges. Barsyte-Lovejoy et al. [@B52] showed that down regulation of*H19* gene attenuated the clonogenicity of lung cancer and breast cancer. They also provided a strong association between *H19* gene expression and primary lung and breast carcinomas. By now, some SNPs located on *H19* gene were identified to be associated with cancer susceptibility. In a study conducted by Guo et al. [@B53], it was found that rs217727 AA genotype of *H19* gene contributes to the susceptibility of oral squamous cell carcinoma in Chinese population. Li et al. [@B28] conducted a case-control study in lung cancer using 555 cases and 618 healthy controls. Their results gave some indication that AA genotype of rs217727 SNP in lncRNA *H19* gene plays a positive role in susceptibility to lung cancer.

We have previously conducted an initial investigation of how *H19* gene SNPs (rs2839698, rs3024270, and rs217727) regulate the risk of neuroblastoma in Chinese population [@B54]. At that time, we only genotyped 393 neuroblastoma patients and 812 control subjects from two hospitals. Our previous results failed to reveal significant associations of the three selected polymorphisms and neuroblastoma susceptibility, in separated and combined analyses. However, we detected an increased neuroblastoma risk in rs3024270 GG genotype in female Chinese children. SNPs analyzed in our previous and the current studies are all located in the *H19* gene. It has been elucidated that these SNPs altered the folding architectures of *H19* gene, which may result in changes of *H19* gene expression or functions [@B55]. Given that lncRNA *H19* gene is critical in carcinogenesis, better understanding is needed of how lncRNA *H19* gene SNPs might impact neuroblastoma risk. Herein, we adopted a larger sample size enrolled from six hospitals in China to get a more generalized conclusion. Again, we failed to detect the impact of *H19* gene SNPs on the risk of neuroblastoma. Moreover, the contributing role of rs3024270 GG in neuroblastoma risk in female Chinese children found in our previous study disappeared in the current larger study. Such conclusion inconsistency may be attributed to the relative compromised statistic power caused by the small sample size in the stratification analysis.

Strength of the current study also accompany some limitations. First, statistic power might be compromised as sample size is not large enough, although this is a multi-center study. Second, as a hospital-based case-control study, inclusion of the non-representative subjects in this study may result in inherent selection bias. Third, conclusions obtained here lack generalizability as subjects are all genetic Chinese descendants. Therefore, cautions should be taken if extrapolated the current conclusion to other populations. Fourth, the selected SNPs were based on prior knowledge of potentially functional SNPs. Other important tagging SNPs within *H19* gene may be omitted. Last, environment factors and gene-environment interactions could not be assessed in the current study, with the absence of environmental data.

In conclusion, here we failed to provide the possibility of lncRNA *H19* gene SNPs in predicting neuroblastoma risk. Our study serves as a basis for future replication studies in independent populations or for functional studies of lncRNA *H19* gene SNPs in neuroblastoma risk.
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Associations between *H19* polymorphisms and neuroblastoma susceptibility

  ------------------------------------------------------------------------------------------------------------------------------------
  Genotype                                Cases\        Controls\      *P*^a^   Crude OR\          *P*     Adjusted OR\       *P*^b^
                                          (N=700)       (N=1514)                (95% CI)                   (95% CI) ^b^       
  --------------------------------------- ------------- -------------- -------- ------------------ ------- ------------------ --------
  rs2839698 G\>A (HWE=0.406)                                                                                                  

  GG                                      331 (47.29)   704 (46.50)             1.00                       1.00               

  AG                                      300 (42.86)   667 (44.06)             0.96 (0.79-1.16)   0.646   0.96 (0.79-1.16)   0.658

  AA                                      69 (9.86)     143 (9.45)              1.03 (0.75-1.41)   0.871   1.04 (0.76-1.43)   0.805

  Additive                                                             0.858    0.99 (0.86-1.14)   0.900   1.00 (0.87-1.14)   0.956

  Dominant                                369 (52.71)   810 (53.50)    0.730    0.97 (0.81-1.16)   0.730   0.97 (0.81-1.16)   0.762

  Recessive                               631 (90.14)   1371 (90.55)   0.759    1.05 (0.78-1.42)   0.758   1.06 (0.79-1.44)   0.696

  rs3024270 C\>G (HWE=0.162)                                                                                                  

  CC                                      184 (26.29)   415 (27.41)             1.00                       1.00               

  CG                                      362 (51.71)   781 (51.59)             1.05 (0.84-1.29)   0.684   1.05 (0.85-1.30)   0.679

  GG                                      154 (22.00)   318 (21.00)             1.09 (0.84-1.42)   0.505   1.09 (0.84-1.42)   0.505

  Additive                                                             0.799    1.05 (0.92-1.19)   0.503   1.05 (0.92-1.19)   0.503

  Dominant                                516 (73.71)   1099 (72.59)   0.580    1.06 (0.87-1.30)   0.580   1.06 (0.87-1.30)   0.576

  Recessive                               546 (78.00)   1196 (79.00)   0.595    1.06 (0.85-1.32)   0.595   1.06 (0.85-1.32)   0.598

  rs217727 G\>A (HWE=0.744)                                                                                                   

  GG                                      331 (47.29)   679 (44.85)             1.00                       1.00               

  AG                                      289 (41.29)   674 (44.52)             0.88 (0.73-1.06)   0.187   0.88 (0.72-1.06)   0.172

  AA                                      80 (11.43)    161 (10.63)             1.02 (0.76-1.37)   0.900   1.02 (0.75-1.37)   0.922

  Additive                                                             0.359    0.96 (0.84-1.10)   0.591   0.96 (0.84-1.10)   0.561

  Dominant                                369 (52.71)   835 (55.15)    0.284    0.91 (0.76-1.09)   0.284   0.90 (0.75-1.08)   0.263

  Recessive                               620 (88.57)   1353 (89.37)   0.577    1.08 (0.82-1.44)   0.577   1.08 (0.81-1.44)   0.586

  Combined effect of risk genotypes ^c^                                                                                       

  0                                       112 (16.00)   258 (17.04)             1.00                       1.00               

  1                                       511 (73.00)   1109 (73.25)            1.06 (0.83-1.36)   0.634   1.06 (0.83-1.36)   0.643

  2                                       77 (11.00)    147 (9.71)              1.21 (0.85-1.72)   0.298   1.22 (0.86-1.74)   0.272

  1-2                                     588 (84.00)   1256 (82.96)   0.542    1.08 (0.85-1.37)   0.542   1.08 (0.85-1.38)   0.542
  ------------------------------------------------------------------------------------------------------------------------------------

OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium. ^a^ χ^2^ test for genotype distributions between neuroblastoma patients and cancer-free controls. ^b^ Adjusted for age and gender. ^c^ Risk genotypes were carriers with rs2839698 AA, rs3024270 CG/GG and rs217727 AA genotypes.

###### 

Stratification analysis for association between *H19* genotypes and neuroblastoma susceptibility

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables         rs2839698\       AOR (95% CI)^a^   *P*^a^             rs3024270\       AOR (95% CI)^a^   *P*^a^     rs217727\          AOR (95% CI)^a^   *P*^a^     Risk genotypes\   AOR (95% CI)^a^    *P*^a^                                          
                    (case/control)                                        (case/control)                                (case/control)                                  (case/control)                                                                       
  ----------------- ---------------- ----------------- ------------------ ---------------- ----------------- ---------- ------------------ ----------------- ---------- ----------------- ------------------ -------- -------- ---------- ------------------ -------
  Age, month                                                                                                                                                                                                                                                 

  ≤18               243/554          31/61             1.14 (0.72-1.80)   0.589            69/182            205/433    1.25 (0.90-1.72)   0.184             248/538    26/77             0.73 (0.46-1.17)   0.189    44/107   230/508    1.09 (0.74-1.60)   0.662

  \>18              388/817          38/82             0.97 (0.65-1.45)   0.880            115/233           311/666    0.95 (0.73-1.23)   0.679             372/815    54/84             1.40 (0.98-2.02)   0.068    68/151   358/748    1.06 (0.78-1.45)   0.703

  Gender                                                                                                                                                                                                                                                     

  Female            273/600          34/55             1.37 (0.87-2.15)   0.177            76/188            231/467    1.22 (0.90-1.67)   0.206             274/581    33/74             0.93 (0.60-1.44)   0.744    49/117   258/538    1.13 (0.78-1.63)   0.520

  Male              358/771          35/88             0.87 (0.57-1.31)   0.490            108/227           285/632    0.95 (0.73-1.24)   0.700             346/772    47/87             1.21 (0.83-1.76)   0.325    63/141   330/718    1.03 (0.75-1.43)   0.848

  Sites of origin                                                                                                                                                                                                                                            

  Adrenal gland     196/1371         19/143            0.94 (0.57-1.55)   0.808            58/415            157/1099   1.02 (0.74-1.40)   0.927             185/1353   30/161            1.38 (0.90-2.10)   0.138    34/258   181/1256   1.09 (0.74-1.61)   0.673

  Retroperitoneal   219/1371         21/143            0.92 (0.57-1.49)   0.746            61/415            179/1099   1.10 (0.81-1.51)   0.544             217/1353   23/161            0.90 (0.57-1.42)   0.641    38/258   202/1256   1.09 (0.75-1.58)   0.663

  Mediastinum       157/1371         20/143            1.24 (0.75-2.04)   0.398            45/415            132/1099   1.12 (0.78-1.60)   0.530             157/1353   20/161            1.06 (0.65-1.74)   0.814    26/258   151/1256   1.21 (0.78-1.87)   0.394

  Others            52/1371          8/143             1.44 (0.67-3.10)   0.347            15/415            45/1099    1.14 (0.63-2.07)   0.671             55/1353    5/161             0.76 (0.30-1.92)   0.559    11/258   49/1256    0.92 (0.47-1.79)   0.796

  Clinical stages                                                                                                                                                                                                                                            

  I+II+4s           311/1371         34/143            1.05 (0.71-1.55)   0.823            97/415            248/1099   0.97 (0.75-1.26)   0.806             304/1353   41/161            1.13 (0.79-1.63)   0.504    58/258   287/1256   1.02 (0.75-1.39)   0.902

  III+IV            297/1371         33/143            1.11 (0.74-1.66)   0.616            80/415            250/1099   1.18 (0.90-1.56)   0.233             294/1353   36/161            1.03 (0.70-1.52)   0.883    50/258   280/1256   1.16 (0.83-1.61)   0.396
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AOR, adjusted odds ratio; CI, confidence interval. ^a^ Adjusted for age and gender, omitting the corresponding stratify factor.

###### 

The frequency of inferred haplotypes of *H19* based on observed genotypes and their association with neuroblastoma susceptibility

  -----------------------------------------------------------------------------------------------------
  Haplotypes ^a^   Cases\        Controls\      Crude OR\          *P*     Adjusted OR ^b^\   *P* ^b^
                   (n=1400)      (n=3028)       (95% CI)                   (95% CI)           
  ---------------- ------------- -------------- ------------------ ------- ------------------ ---------
  GCG              496 (35.43)   1098 (36.26)   1.00                       1.00               

  GCA              226 (16.14)   501 (16.55)    1.00 (0.83-1.21)   0.988   1.00 (0.82-1.20)   0.966

  GGG              156 (11.14)   303 (10.01)    1.14 (0.91-1.42)   0.245   1.14 (0.91-1.42)   0.259

  GGA              84 (6.00)     173 (5.71)     1.08 (0.81-1.42)   0.615   1.07 (0.80-1.41)   0.659

  ACG              2 (0.14)      5 (0.17)       0.89 (0.17-4.58)   0.885   0.95 (0.18-4.90)   0.947

  ACA              6 (0.43)      7 (0.23)       1.90 (0.63-5.68)   0.252   1.96 (0.65-5.87)   0.230

  AGG              297 (21.21)   626 (20.67)    1.05 (0.88-1.25)   0.581   1.05 (0.89-1.25)   0.558

  AGA              133 (9.50)    315 (10.40)    0.94 (0.74-1.18)   0.563   0.94 (0.74-1.18)   0.567
  -----------------------------------------------------------------------------------------------------

OR, odds ratio; CI, confidence interval. ^a^ The haplotypes order were rs2839698, rs3024270, and rs217727. ^b^ Obtained in logistic regression models with adjustment for age and gender.
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